<DOC>
	<DOCNO>NCT00996983</DOCNO>
	<brief_summary>Neuropathic pain difficult control partially sensitive opioid analgesic , require addition therapy antidepressant epileptic . Ziconotide drug use treat neuropathic pain patient inadequate pain control prior combination medicine .</brief_summary>
	<brief_title>Safety Activity Study Intrathecally Administered Ziconotide Neuropathic Pain Patients With Cancer</brief_title>
	<detailed_description>The purpose study evaluate effect tolerability intrathecal ziconotide cancer patient suffer severe neuropathic pain control previous therapy .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Ziconotide</mesh_term>
	<mesh_term>omega-Conotoxins</mesh_term>
	<criteria>Diagnosis neoplasm Neuropathic pain level VASPI &gt; = 6 ( 010 scale ) Inadequate pain relief opioid analgesic adjuvant Age &gt; = 18 year Performance status ECOG 02 Life expectancy least one month Adequate contraception woman childbearing potential Signed Informed Consent Use experimental drug within previous 30 day Pregnancy lactation Contraindication use intrathecal analgesic , include active infection condition could alter circulation cerebrospinal fluid Presence cerebral metastasis INR &gt; 2 Contraindication use ziconotide Unable unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>